 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ZW171 / Zymeworks
ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors (Section 23; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_5105;
Importantly, ZW171 exhibited potent tumor growth inhibition in multiple established tumor models. Collectively, these data suggest that ZW171 has the potential to be an efficacious and safe therapeutic for the treatment of MSLN-expressing cancers.